Academic teams and startups published converging proofs that CAR‑T cells can be generated and genomically integrated inside living hosts. UCSF researchers reported a dual‑vector system that achieved targeted, site‑specific insertion of large transgenes into circulating T cells and cured multiple tumor models in humanized mice. Separately, a Nature paper described precision in vivo T‑cell reprogramming—using targeted delivery systems that prioritize cell specificity and genomic locus control—demonstrating tumor clearance in solid and hematologic models. Both reports emphasize stable integration, improved safety profiles versus random viral insertion, and the potential to eliminate centralized ex‑vivo manufacturing.